Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1038039

	registered interest
	date	08/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pregnancy Tests
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will make an assessment of the merits in the conclusions of the 2018 report by Professor Carl Heneghan on oral hormones pregnancy tests and the risks of congenital malformations; and if he will make a statement.
	tabling member constituency	Bolton South East
	tabling member printed	Yasmin Qureshi
	uin	206297
	answer	answer is ministerial correction date of answer 11/01/2019 answer text <p>In line with the Government’s commitment to review any new evidence in relation to hormone pregnancy tests, the Commission on Human Medicines is convening a new expert group to conduct an independent scientific review of the publication by Professor Carl Heneghan. In addition, the European Medicines Agency’s Committee for Medicinal Products for Human Use is conducting a review of the paper at European Union level, at the request of the Medicines and Healthcare products Regulatory Agency. Once this paper has been fully considered the findings will be made public.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 11/01/2019 15:18:24 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	3924 label Biography information for Yasmin Qureshi

1064025

	registered interest
	date	19/02/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Dementia
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the report of the Alzheimer's Society entitled Dementia – the true cost: Fixing the care crisis, published in May 2018, whether the Government plans to (a) cover the extra health charges that dementia patients accrue as a result of their condition and (b) ensure that everyone with dementia has a care navigator to support access to timely, preventative and integrated support.
	tabling member constituency	Bolton South East
	tabling member printed	Yasmin Qureshi
	uin	223223
	answer	answer is ministerial correction date of answer 27/02/2019 answer text <p>The Green Paper on adult social care will bring forward proposals to ensure that all adults, including those living with dementia, receive high quality care whenever they need it. It will also bring forward ideas for including an element of risk pooling in the system, which will help to protect people from the highest costs.</p><p> </p><p>We remain committed to delivering the Challenge on Dementia 2020 in full to make England the best country in the world for dementia care by 2020. The March 2016 implementation plan details how the commitments in the Challenge, across four core themes of risk reduction, health and care, awareness and social action, and research will be met.</p><p> </p><p>The Implementation Plan envisages general practitioners (GPs) playing a leading role in ensuring coordination and continuity of care for people with dementia. We have recently undertaken a review of our implementation plan to reflect on what has been achieved so far and what more we need to do to achieve our goals by 2020. As a result of that we will be reviewing the role of GPs and whether they remain the staff group best placed to lead on care coordination in all cases.</p><p> </p><p>In addition, the NHS Long Term Plan commits to better support for people with dementia in the community and ongoing close work with the voluntary sector, for example supporting Alzheimer’s Society’s dementia connect programme.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 27/02/2019 11:12:07 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	3924 label Biography information for Yasmin Qureshi

1041249

	registered interest
	date	14/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will publish (a) a list of medicines for which there is a supply risk in the event of the UK leaving the EU without a deal and (b) a plan to mitigate those supply risks.
	tabling member constituency	Ilford North
	tabling member printed	Wes Streeting
	uin	208298
	answer	answer is ministerial correction date of answer 17/01/2019 answer text <p>The Department’s plans to ensure the supply of medicines in the event of the United Kingdom leaving the European Union without a deal have been subject to scrutiny by a number of Parliamentary Committees, including the Public Accounts Committee, the Health and Social Care Committee, the EU Exit Committee and the House of Lords EU Home Affairs Sub-Committee. The Department is also working closely with suppliers, their supply chains, health services and devolved administrations to maintain the continuity of medicines supply in a ‘no deal’ EU exit scenario.</p><p> </p><p>We are unable to publish the list of medicines requested. To reassure participating companies, we have committed to treating all information received confidentially, securely and to using it only for the purposes of the Department’s contingency programme. That means not introducing information about a specific company, medicine or supply route into the public domain.</p><p> </p><p>On 23 August 2018, the Department wrote to all pharmaceutical companies that supply prescription-only and pharmacy medicines to the UK that come from, or via, the EU or European Economic Area (EEA), asking them to ensure a minimum of six weeks’ additional supply in the UK, over and above existing business-as-usual buffer stocks, by 29 March 2019. We recognise, however, that certain medicines with short shelf lives, including medical radioisotopes, cannot be reasonably stockpiled. Where these medicines are imported from the EU or EEA, we have asked that suppliers ensure in advance plans to air freight these medicines from the EU in the event of a ‘no deal’ exit.</p><p> </p><p>Additionally, on 7 December 2018, the Department wrote to pharmaceutical companies that supply licensed medicines to the UK from or via the EU/EEA and/or manufacture medicines in the UK, informing them of the updated reasonable worst-case scenario border disruption planning assumptions and asking them about their current transportation routes and their ability to re-route their supply chains if they currently rely on Dover and/or Folkestone.</p><p> </p><p>We have received very good engagement from industry who share our aims of ensuring continuity of medicines supply for patients is maintained and that suppliers are able to cope with any potential delays at the border that may arise in the short term in the event of a ‘no deal’ exit.</p> answering member constituency Wimbledon answering member printed Stephen Hammond grouped question UIN 208297 question first answered 17/01/2019 16:27:06 answering member 1585 label Biography information for Stephen Hammond
	tabling member	4504 label Biography information for Wes Streeting

1041248

	registered interest
	date	14/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether his Department's plans to ensure the supply of medicines in the event of the UK leaving the EU without a deal (a) have been or (b) will be subjected to an independent evaluation.
	tabling member constituency	Ilford North
	tabling member printed	Wes Streeting
	uin	208297
	answer	answer is ministerial correction date of answer 17/01/2019 answer text <p>The Department’s plans to ensure the supply of medicines in the event of the United Kingdom leaving the European Union without a deal have been subject to scrutiny by a number of Parliamentary Committees, including the Public Accounts Committee, the Health and Social Care Committee, the EU Exit Committee and the House of Lords EU Home Affairs Sub-Committee. The Department is also working closely with suppliers, their supply chains, health services and devolved administrations to maintain the continuity of medicines supply in a ‘no deal’ EU exit scenario.</p><p> </p><p>We are unable to publish the list of medicines requested. To reassure participating companies, we have committed to treating all information received confidentially, securely and to using it only for the purposes of the Department’s contingency programme. That means not introducing information about a specific company, medicine or supply route into the public domain.</p><p> </p><p>On 23 August 2018, the Department wrote to all pharmaceutical companies that supply prescription-only and pharmacy medicines to the UK that come from, or via, the EU or European Economic Area (EEA), asking them to ensure a minimum of six weeks’ additional supply in the UK, over and above existing business-as-usual buffer stocks, by 29 March 2019. We recognise, however, that certain medicines with short shelf lives, including medical radioisotopes, cannot be reasonably stockpiled. Where these medicines are imported from the EU or EEA, we have asked that suppliers ensure in advance plans to air freight these medicines from the EU in the event of a ‘no deal’ exit.</p><p> </p><p>Additionally, on 7 December 2018, the Department wrote to pharmaceutical companies that supply licensed medicines to the UK from or via the EU/EEA and/or manufacture medicines in the UK, informing them of the updated reasonable worst-case scenario border disruption planning assumptions and asking them about their current transportation routes and their ability to re-route their supply chains if they currently rely on Dover and/or Folkestone.</p><p> </p><p>We have received very good engagement from industry who share our aims of ensuring continuity of medicines supply for patients is maintained and that suppliers are able to cope with any potential delays at the border that may arise in the short term in the event of a ‘no deal’ exit.</p> answering member constituency Wimbledon answering member printed Stephen Hammond grouped question UIN 208298 question first answered 17/01/2019 16:27:06 answering member 1585 label Biography information for Stephen Hammond
	tabling member	4504 label Biography information for Wes Streeting

1046874

	registered interest
	date	23/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Chronic Fatigue Syndrome: Research
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent funding has been made available for research into myalgic encephalomyelitis.
	tabling member constituency	Bath
	tabling member printed	Wera Hobhouse
	uin	211844
	answer	answer is ministerial correction date of answer 31/01/2019 answer text <p>The National Institute for Health Research (NIHR), on behalf of the Department, funded £1,495,363 of programme research on myalgic encephalomyelitis (ME), also known as chronic fatigue syndrome (CFS), over the last three financial years (up to 2017/18). Further information on this research is available through the NIHR Journals Library at the following link:</p><p><a href="https://www.journalslibrary.nihr.ac.uk/programmes/" target="_blank">https://www.journalslibrary.nihr.ac.uk/programmes/</a></p><p>The NIHR welcomes funding applications for research into any aspect of human health, including ME/CFS; it is not usual practice to ring-fence funds for particular topics or conditions. Applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 31/01/2019 17:21:07 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	4602 label Biography information for Wera Hobhouse

1047012

	registered interest
	date	23/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Haemochromatosis: Research
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what funding his Department has made available for research into haemochromatosis.
	tabling member constituency	Bath
	tabling member printed	Wera Hobhouse
	uin	211845
	answer	answer is ministerial correction date of answer 31/01/2019 answer text <p>The Department’s National Institute for Health Research (NIHR) welcomes funding applications for research into any aspect of human health, including haemochromatosis. Applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality. Information on individual projects funded by the NIHR can be found at the following link:</p><p> </p><p><a href="https://www.journalslibrary.nihr.ac.uk/programmes/" target="_blank">https://www.journalslibrary.nihr.ac.uk/programmes/</a></p><p> </p><p>NIHR funded infrastructure is currently supporting a clinical trial into haemochromatosis, through the NIHR Clinical Research Network Coordinating Centre. The trial is testing a new formulation of hepcidin as a treatment for haemochromatosis.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 31/01/2019 17:21:56 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	4602 label Biography information for Wera Hobhouse

1029558

	registered interest
	date	20/12/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Compulsorily Detained Psychiatric Patients
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the effectiveness of the (a) support and (b) treatment for people detained under the Mental Health Act 1983.
	tabling member constituency	Caerphilly
	tabling member printed	Wayne David
	uin	204428
	answer	answer is ministerial correction date of answer 07/01/2019 answer text <p>The Care Quality Commission has a statutory duty to monitor how mental health providers exercise powers and discharge their duties when people are detained under the Mental Health Act 1983. It reports annually, and its most recent report Monitoring the Mental Health Act in 2016/17 was published in February 2018. The report contains a specific chapter on care, support and treatment in hospital. It is available at the following link:</p><p> </p><p><a href="http://www.cqc.org.uk/sites/default/files/20180227_mhareport_web.pdf" target="_blank">www.cqc.org.uk/sites/default/files/20180227_mhareport_web.pdf</a></p><p> </p><p>The Government has committed to reform mental health legislation. As a first step towards this, the Prime Minister asked Professor Sir Simon Wessely to chair a full and independent review of the Mental Health Act 1983. Modernising the Mental Health Act Increasing choice, reducing compulsion, the final report of the Independent Review of the Mental Health Act, was published in December. The Government will consider the report and its recommendations in detail, and will respond in due course.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 07/01/2019 15:30:43 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	1398 label Biography information for Wayne David

1037845

	registered interest
	date	08/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what the timeframe is for the introduction of Serious Shortage Protocols for medicine.
	tabling member constituency	Caerphilly
	tabling member printed	Wayne David
	uin	206271
	answer	answer is ministerial correction date of answer 11/01/2019 answer text <p>The Department engaged with a wide range of stakeholder representative bodies about the proposals and also conducted a written consultation. The Department received 47 responses to its written consultation including from industry, patients’, pharmacists’ and doctors’ representative bodies. The responses to the consultation were broadly supportive.</p><p> </p><p>The Statutory Instrument is expected to be laid shortly and come into force before 29 March. Any serious shortage protocol would be developed with and signed off by clinicians. Only if clinicians deem it appropriate, an alternative quantity, strength, pharmaceutical form or medicine can be dispensed in line with the protocol.</p><p> </p><p>A protocol is only one of the tools that can be used to manage shortages. The Department manages shortages in collaboration with manufacturers and suppliers, the National Health Service and the Medicines and Healthcare products Regulatory Agency and will continue to do so. A protocol would only be introduced in case of a serious shortage, if it would help manage the supply situation and if clinicians think it is appropriate, taking account of the risks to and well-being of patients and after discussion with the manufacturer and/or marketing authorisation holder.</p><p> </p><p>Any serious shortage would be time limited and the protocol itself would indicate the period during which it has effect.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 206270 206272 206273 question first answered 11/01/2019 13:10:58 answering member 4067 label Biography information for Steve Brine
	tabling member	1398 label Biography information for Wayne David

1037849

	registered interest
	date	08/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether the Serious Shortage Protocols for medicines are time-limited.
	tabling member constituency	Caerphilly
	tabling member printed	Wayne David
	uin	206272
	answer	answer is ministerial correction date of answer 11/01/2019 answer text <p>The Department engaged with a wide range of stakeholder representative bodies about the proposals and also conducted a written consultation. The Department received 47 responses to its written consultation including from industry, patients’, pharmacists’ and doctors’ representative bodies. The responses to the consultation were broadly supportive.</p><p> </p><p>The Statutory Instrument is expected to be laid shortly and come into force before 29 March. Any serious shortage protocol would be developed with and signed off by clinicians. Only if clinicians deem it appropriate, an alternative quantity, strength, pharmaceutical form or medicine can be dispensed in line with the protocol.</p><p> </p><p>A protocol is only one of the tools that can be used to manage shortages. The Department manages shortages in collaboration with manufacturers and suppliers, the National Health Service and the Medicines and Healthcare products Regulatory Agency and will continue to do so. A protocol would only be introduced in case of a serious shortage, if it would help manage the supply situation and if clinicians think it is appropriate, taking account of the risks to and well-being of patients and after discussion with the manufacturer and/or marketing authorisation holder.</p><p> </p><p>Any serious shortage would be time limited and the protocol itself would indicate the period during which it has effect.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 206270 206271 206273 question first answered 11/01/2019 13:10:58 answering member 4067 label Biography information for Steve Brine
	tabling member	1398 label Biography information for Wayne David

1037850

	registered interest
	date	08/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what safeguards his Department has put in place to ensure that medical Serious Shortage Protocols do not pose risk to the well-being of patients.
	tabling member constituency	Caerphilly
	tabling member printed	Wayne David
	uin	206273
	answer	answer is ministerial correction date of answer 11/01/2019 answer text <p>The Department engaged with a wide range of stakeholder representative bodies about the proposals and also conducted a written consultation. The Department received 47 responses to its written consultation including from industry, patients’, pharmacists’ and doctors’ representative bodies. The responses to the consultation were broadly supportive.</p><p> </p><p>The Statutory Instrument is expected to be laid shortly and come into force before 29 March. Any serious shortage protocol would be developed with and signed off by clinicians. Only if clinicians deem it appropriate, an alternative quantity, strength, pharmaceutical form or medicine can be dispensed in line with the protocol.</p><p> </p><p>A protocol is only one of the tools that can be used to manage shortages. The Department manages shortages in collaboration with manufacturers and suppliers, the National Health Service and the Medicines and Healthcare products Regulatory Agency and will continue to do so. A protocol would only be introduced in case of a serious shortage, if it would help manage the supply situation and if clinicians think it is appropriate, taking account of the risks to and well-being of patients and after discussion with the manufacturer and/or marketing authorisation holder.</p><p> </p><p>Any serious shortage would be time limited and the protocol itself would indicate the period during which it has effect.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 206270 206271 206272 question first answered 11/01/2019 13:10:58 answering member 4067 label Biography information for Steve Brine
	tabling member	1398 label Biography information for Wayne David